Delayed gastric emptying can impair absorption of L-dopa, thereby contributing to motor
fluctuations. Camicinal (GSK962040), is a gastroprokinetic, which is being assessed for its
effect on the absorption of L-dopa and the symptoms of Parkinson’s Disease.
Gastroprokinetic drugs increase the movement of ingested material through the GI tract.
Patients were given either 50mg camicinal daily for 7 to 9
days or were taking a placebo. Average time to reach
maximum L-dopa concentration by taking camicinal was
reduced, indicating more rapid absorption of L-dopa.
Camicinal resulted in significant reduction in OFF time,
reducing it by 2 hours 18 minutes. There was a significant
increase in ON time, increasing it by 1 hour 52 minutes. There
was also a significant decrease in mean total MDS-UPDRS
score (Parkinson’s Disease symptoms). Camicinal treatment
was generally well tolerated.
Parkinson’s Disease symptom improvement with the use of camicinal occurred in parallel
with a more rapid absorption of L-dopa. This study provides evidence of an improvement of
the motor response to L-dopa in people with Parkinson’s Disease treated with camicinal.
Reference : Movement Disorders [2017] Dec 26 [Epub ahead of print] (S.L.Marrinan,
T.Otiker, L.S.Vasist, R.A.Gibson, B.K.Sarai, M.E.Barton, D.B.Richards, P.M.Hellström,
D.Nyholm, G.E.Dukes, D.J.Burn)
Complete abstract : http://www.ncbi.nlm.nih.gov/pubmed/29278279
http://www.viartis.net/parkinsons.disease/news/171231.pdf
No comments:
Post a Comment